Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co Total Equity Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) has a Total Equity of HK$13,887 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Shenzhen Hepalink Pharmaceutical Group Co and its competitors.
Is Shenzhen Hepalink Pharmaceutical Group Co's Total Equity too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Total Equity is HK$13,887 Mil. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Total Equity compare to ZTS?
Shenzhen Hepalink Pharmaceutical Group Co's Total Equity of HK$13,887 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Shenzhen Hepalink Pharmaceutical Group Co's current Total Equity is HK$13,887 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) is currently considered Fairly Valued. The stock's GF Value™ is HK$4.59, compared to a current price of HK$4.53 — trading 1.3% below its estimated fair value. The current Total Equity is HK$13,887 Mil. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989), the current Total Equity is HK$13,887 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of HK$4.53 is trading 1.3% below its estimated GF Value™ of HK$4.59.
GuruFocus considers Shenzhen Hepalink Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for HKSE:09989:
Total Equity: HK$13,887 Mil
GF Value™: HK$4.59 vs. price of HK$4.53 (1.3% below fair value)
No single metric tells the full story. See the HKSE:09989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
83GF Score
Get the complete analysis for HKSE:09989
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09989 has been successfully added to your 
